Table 1.
Compounds with senolytic properties tested in clinical trials and common associated toxicities. AD, Alzheimer’s disease; IPF, idiopathic pulmonary fibrosis; GI, gastrointestinal.
| Drug | Primary Targets | Clinical Trials to date | Clinical toxicity |
|---|---|---|---|
| ABT263 (Navitoclax) | Bcl‐2 | Solid and haematological malignancy | Thrombocytopenia, neutropenia |
| UBX1325 | Bcl‐xl | Diabetic macular oedema | None reported to date |
| Dasatinib | Bcr/Abl, SRC, Ephrin | Anaemia, thrombocytopenia, neutropenia, pleural effusion, GI disturbance | |
| + Quercetin | Bcl‐2 IGF‐1, HIF‐1α | Frailty, AD, ageing, chronic kidney disease, IPF, bone health | None reported to date |
| + Fisetin | Multiple targets | Frailty, ageing, bone health | None reported to date |
| + Luteolin | Multiple targets | None in senescence | Raised liver enzymes (mice) |
| Cardiac glycoside | Na+/K+ ATPase | None in senescence | Arrhythmia, GI disturbance, visual disturbance |
| UBX0101 | MDM2 | Osteoarthritis | None reported to date |
| Geldanamycin | HSP‐90 | Solid and haematological malignancy | Hepatoxicity |
| Tanespimycin | HSP‐90 | Solid and haematological malignancy | GI disturbances, fatigue |
| Alvespimycin | HSP‐90 | Solid and haematological malignancy | Neutropenia, fatigue, Gi disturbances |
| AZD8055 | mTOR | Solid malignancy | Hepatotoxicity |